The U.S. Food and Drug Administration approved Gamida Cell Ltd.'s Omisirge (omidubicel-onlv) cell therapy for patients with blood cancers to reduce risk of infection following stem cell transplantation.
Introducing bacteria to a tumour's microenvironment creates a state of acute inflammation that triggers the immune system's primary responder cells to attack rather than protect a tumour.